{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wedge DC"],"funding":["Cancer Research UK","The Francis Crick Institute","National Institute for Health Research (NIHR)","NCI NIH HHS","Cancer Foundation Finland sr","Wellcome Trust"],"pagination":["682-692"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6372064"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50(5)"],"pubmed_abstract":["Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for NEAT1 and FOXA1 acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion-negative cancers. Computational chemoge"],"journal":["Nature genetics"],"pubmed_title":["Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets."],"pmcid":["PMC6372064"],"funding_grant_id":["A11566","26718","A14835","A17528","P30 CA008748","22530","22897","170104","23187","A7990","15007","17528","11566","14835","19556","160116","CL-2014-14-004","20406","A6743","NF-SI-0510-10096","A23187","22744","21777","A22530","NF-SI-0513-10121","CL-2008-22-001","NF-SI-0509-10242","150069","10202","130073"],"pubmed_authors":["Gundem G","Thompson A","Foster CS","Lynch AG","Martincorena I","Van As N","Zhang H","Gnanapragasam V","Berney DM","Lu YJ","Kumar P","Ahmed M","Gill P","Whitaker H","Rowe E","Teague J","Brewer DS","Ghori M","Easton DF","Sander C","Neal DE","Tavare S","Livni N","Fraser M","Greenman C","Kote-Jarai Z","Ng A","McDermott U","Eeles RA","Edwards S","Attard G","Dentro S","Matthews L","Woodcock DJ","Fisher C","Stebbings L","Corbishley C","Menzies A","TCGA Consortium","Hazell S","Lambert A","Cooper CS","Hawkins S","Al-Lazikani B","Cahill D","Howat W","Isaacs W","Verrill C","Warren AY","Luxton H","Bova GS","Van Loo P","Dadaev T","Mayer E","Jones D","Wedge DC","Nicol D","Massie CE","Thomas S","Dudderidge T","Workman P","Visakorpi T","Shah NC","McLaren S","Raine K","Futreal A","de Bono J","Yu Y","Dennis N","Alexandrov LB","Butler A","Kay J","Leongamornlert D","Bristow RG","Camacho N","Merson S","CAMCAP Study Group","Mitchell T","Karaszi K","Zamora J","Bancroft E","Ogden C","Boutros PC","Khoo V","Bo V","Hamdy FC","Kremeyer B","Marsden L"],"additional_accession":[]},"is_claimable":false,"name":"Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.","description":"Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for NEAT1 and FOXA1 acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion-negative cancers. Computational chemoge","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 May","modification":"2026-05-03T02:04:45.847Z","creation":"2025-05-29T19:54:54.656Z"},"accession":"S-EPMC6372064","cross_references":{"pubmed":["29662167"],"doi":["10.1038/s41588-018-0086-z"]}}